封面
市場調查報告書
商品編碼
1543628

製藥和生物技術領域的合資交易(2016-2024)

Joint Venture Deals in Pharmaceuticals and Biotechnology 2016-2024

出版日期: | 出版商: Current Partnering | 英文 250+ Pages | 商品交期: 最快1-2個工作天內

價格

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

本報告深入了解並分析公司如何以及為何進行合資交易。

本報告提供了2016年至2024年合資計畫的詳細資訊。

本報告提供了雙方宣布的合資交易的付款條款的資訊。這些資料提供了有關支付條款和其他交易條款的寶貴見解。

了解潛在合作夥伴談判條款的彈性,並深入了解談判過程,以了解條款談判期間的預期結果。許多小型企業會要求提供付款條件的詳細信息,但在包括付款方式和權利如何轉讓時,細節是關鍵。

本報告提供了當前協議交易/合作資料庫中記錄的自2016年以來宣布的合資交易的完整列表,包括可用的財務條款的連結。

主要優點

本報告為讀者提供了以下主要好處:

  • 了解2016年以來的交易完成趨勢
  • 查看合資企業交易
  • 基準分析:確定交易的市場價值
  • 財務狀況
  • 交易清單:依公司名稱(A-Z)、依治療領域、依技術類型
  • 主要交易(金額基礎)
  • 最活躍的交易撮合者
  • 每筆交易的資產識別和交易條件
  • 取得合約文件:深入了解交易結構
  • 實質審查:評估擬議交易條款對合作夥伴公司的適用性
  • 節省數百小時的研究時間

調查範圍

  • 本報告目的是詳細了解全球領先的生物創業公司之間的合資趨勢和交易結構。

此報告包含以下資訊:

  • 生物製藥產業合資交易趨勢
  • 合資企業交易架構:概述
  • 製藥和生技產業的合資交易記錄列表
  • 主要合資交易(價值基礎)
  • 最活躍的合資企業交易者
  • 合資企業的主要合作夥伴資源

此報告列出了可獲得資訊的交易:

  • 依公司名稱(A-Z)
  • 依交易金額
  • 依治療領域
  • 依技術型
  • 每個交易標題都透過網路連結連結到實際交易記錄的線上版本。
  • 此報告提供了對許可協議的可用合約文件的全面存取。

此報告列出了可獲得資訊的交易:

  • 公司AZ
  • 標題數量
  • 治療領域
  • 技術類型
  • 每個交易標題都透過網路連結連結到實際交易記錄的線上版本,可以輕鬆存取每個合約文件(如果有)。
  • 此報告提供對合資企業交易的可用記錄的全面存取。

合約分析允許實質審查:

  • 授予和選擇了哪些權利?
  • 合約授予了哪些權利?
  • 授予哪些專有權?
  • 合約的付款結構是怎樣的?
  • 如何審核銷售和付款?
  • 合約期限是多久?
  • 合約的主要條款是如何定義的?
  • 如何對待和擁有知識產權?
  • 誰負責商業化?
  • 誰負責開發、供應和製造?
  • 如何管理保密和發布?
  • 如何解決爭議?
  • 什麼情況下可以取消合約?
  • 如果所有者發生變化會怎樣?
  • 已就何種類型的分授權或分包條款達成協議?
  • 公司需要哪些樣板條款?
  • 哪些樣板條款會根據合作夥伴和交易類型的不同而有所不同?
  • 每家公司都主張合約法中的哪一個管轄權?

目錄

執行摘要

第1章 簡介

第2章 合資趨勢

  • 簡介
  • 合資協議的定義
  • 合資企業的趨勢(2016年以來)
    • 簽署合資交易:依年份(2016-2024年)
    • 簽署合資交易:依發展階段(2016-2024年)
    • 簽署合資交易:依行業分類(2016-2024年)
    • 簽署合資交易:依治療領域(2016-2024年)
    • 簽署合資交易:依技術類型(2016-2024年)
    • 簽署合資交易:針對最活躍的公司(2016-2024年)
  • 簽訂合資夥伴關係協議的原因
  • 未來的合資企業

第3章 合資交易結構概述

  • 簡介
  • 合資協議的結構

第4章 重大合營交易

  • 簡介
  • 主要合資交易(價值基礎)

第5章 25 家最活躍合資企業交易者

  • 簡介
  • 最活躍的25 家合資企業交易者

第6章 合資交易清單(含合約明細)

  • 簡介
  • 合資交易協議(2016-2024)
  • 交易清單
  • 交易清單:合資企業交易協議,依公司名稱(A-Z)
  • 交易清單:合資企業交易,依治療領域
  • 交易清單:合資企業交易,依技術類型

關於Wildwood Ventures

  • 目前的合作關係
  • 當前合約
  • Current Partnering的最新報告標題
簡介目錄
Product Code: CP2060

Joint Venture Deals in Pharmaceuticals and Biotechnology provides a detailed understanding and analysis of how and why companies enter joint venture deals.

Fully revised and updated, the report provides details of joint venture deals from 2016 to 2024.

The report provides access to joint venture deal payment terms as announced between the parties. This data provides useful insight into the payment and other deal terms.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered and rights transferred - contract documents provide this insight where press releases and databases do not.

This report contains a comprehensive listing of joint venture deals announced since 2016 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual joint venture contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The initial chapters of this report provide an orientation of joint venture dealmaking and business activities.

Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview and analysis of the trends in joint venture as well as a discussion on the merits of the type of deal.

Chapter 3 provides an overview of the structure of joint venture deals.

Chapter 4 provides a review of the leading joint venture deals since 2016. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.

Chapter 5 provides a comprehensive listing of the top 25 most active joint venture dealmaker companies. Each deal title links via Current Agreements deals and alliances database to an online version of the full deal record, and where available, the actual contract document, providing easy access to each deal record on demand.

Chapter 6 provides a comprehensive and detailed review of joint venture deals organized by company A-Z, therapy, technology and industry type signed and announced since 2016 where a contract document is available. Contract documents provide an indepth insight into the actual deal terms agreed between the parties with respect to the joint venture deal.

The deal directory includes a comprehensive listing of all joint venture deals announced since 2016. Each listing is organized as a deal directory by company A-Z, therapeutic area and technology type. Each deal title links via hyperlink to an online version of the deal record including, where available, the actual contract document.

The report also includes numerous table and figures that illustrate the trends and activities in joint venture dealmaking since 2016.

In conclusion, this report provides everything a prospective dealmaker needs to know about joint venture alliances.

Key benefits

Joint Venture Deals in Pharmaceuticals and Biotechnology provides the reader with the following key benefits:

  • Understand deal trends since 2016
  • Browse joint venture deals
  • Benchmark analysis - identify market value of transactions
  • Financials terms
  • Directory of deals by company A-Z, therapy focus and technology type
  • Leading deals by value
  • Most active dealmakers
  • Identify assets and deal terms for each transaction
  • Access contract documents - insights into deal structures
  • Due diligence - assess suitability of your proposed deal terms for partner companies
  • Save hundreds of hours of research time

Report scope

  • Joint Venture Deals in Pharmaceuticals and Biotechnology is intended to provide the reader with an in-depth understanding of the joint venture trends and structure of deals entered into by leading biopharma companies worldwide.

Joint Venture Deals in Pharmaceuticals and Biotechnology includes:

  • Trends in joint venture dealmaking in the biopharma industry
  • Overview of joint venture deal structure
  • Directory of joint venture deal records covering pharmaceutical and biotechnology
  • The leading joint venture deals by value
  • Most active joint venture dealmakers
  • The leading joint venture partnering resources

In Joint Venture Deals in Pharmaceuticals and Biotechnology, the available deals are listed by:

  • Company A-Z
  • Headline value
  • Therapeutic area
  • Technology type
  • Each deal title links via Weblink to an online version of the actual deal record, providing easy access to each contract document where available.
  • Joint Venture Deals in Pharmaceuticals and Biotechnology provides comprehensive access to available records for joint venture deals, including contract documents where available.

Analyzing contract agreements allows due diligence of:

  • What are the rights granted or optioned?
  • What rights are granted by the agreement?
  • What exclusivity is granted?
  • What is the payment structure for the deal?
  • How are sales and payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are intellectual property rights handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in joint venture dealmaking

  • 2.1. Introduction
  • 2.2. Definition of joint venture deal
  • 2.3. Trends in joint venture deals since 2016
    • 2.3.1. Joint venture dealmaking by year, 2016-2024
    • 2.3.2. Joint venture dealmaking by phase of development, 2016-2024
    • 2.3.3. Joint venture dealmaking by industry sector, 2016-2024
    • 2.3.4. Joint venture dealmaking by therapy area, 2016-2024
    • 2.3.5. Joint venture dealmaking by technology type, 2016-2024
    • 2.3.6. Joint venture dealmaking by most active company, 2016-2024
  • 2.4. Reasons for entering into joint venture partnering deals
  • 2.5. The future of joint venture deals

Chapter 3 - Overview of joint venture deal structure

  • 3.1. Introduction
  • 3.2. Joint venture agreement structure

Chapter 4 - Leading joint venture deals

  • 4.1. Introduction
  • 4.2. Top joint venture deals by value

Chapter 5 - Top 25 most active joint venture dealmakers

  • 5.1. Introduction
  • 5.2. Top 25 most active joint venture dealmakers

Chapter 6 - Joint venture deals including contracts directory

  • 6.1. Introduction
  • 6.2. Joint venture deals with contracts 2016-2024
  • Deal directory
  • Deal directory - joint venture dealmaking by companies A-Z
  • Deal directory - joint venture dealmaking by therapy area
  • Deal directory - joint venture dealmaking by technology type

About Wildwood Ventures

  • Current Partnering
  • Current Agreements
  • Recent report titles from Current Partnering

TABLE OF FIGURES

  • Figure 1: Definition of joint venture deal
  • Figure 2: Trends in joint venture deal announcements, 2016-2024
  • Figure 3: Joint venture deals signed at each phase of development, 2016-2024
  • Figure 4: Joint venture deals by industry sector, 2016-2024
  • Figure 5: Joint venture deals by therapy area, 2016-2024
  • Figure 6: Joint venture deals by technology type, 2016-2024
  • Figure 7: Top 25 most active joint venture dealmakers, 2016-2024
  • Figure 8: Top joint venture deals by value, 2016-2024
  • Figure 9: Most active joint venture dealmakers, 2016-2024